An economic evaluation of the war on cancer

Journal of Health Economics

Volumn 29, Issue 3, 2010, Pages 333-346

  Lakdawalla, Darius N ^c   Sun, Eric C ^a   Jena, Anupam B ^b   Reyes, Carolina M ^d   Goldman, Dana P ^c   Philipson, Tomas J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Economic gains; Life expectancy

Indexed keywords

CANCER; DRUG; HEALTH CARE; LIFE EXPECTANCY; PRIVATE SECTOR; PUBLIC SECTOR; RESEARCH AND DEVELOPMENT;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER REGISTRY; CANCER RESEARCH; CANCER SURVIVAL; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS; DRUG INDUSTRY; ECONOMIC EVALUATION; HEART DISEASE; HYPERTENSION; INCOME; INVESTMENT; LIFE EXPECTANCY; LIFESPAN; LUNG CANCER; LUNG DISEASE; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PROFIT; STROKE;

BIOMEDICAL RESEARCH; COST OF ILLNESS; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; INCOME; LIFE EXPECTANCY; MASS SCREENING; NEOPLASMS; SURVIVAL ANALYSIS; UNITED STATES; VALUE OF LIFE;

UNITED STATES;

EID: 77952542721     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2010.02.006     Document Type: Article

References (38)

1. Aldy, J.E., Viscusi, W.K., 2007. Age Differences in the Value of Statistical Life: Revealed Preference Evidence, Resources For the Future, Discussion Papers.
2. American Cancer Society, 2008. Cancer Facts and Figures 2008. American Cancer Society, Atlanta.
3. Becker, G.S., Murphy, K.M., Philipson, T.J., 2007. The Value of Life Near Its End and Terminal Care. National Bureau of Economic Research Working Paper 1333. Cambridge, MA.
4. Becker G.S., Philipson T.J., Soares R.R. The quantity and quality of life and the evolution of world inequality. American Economic Review 2005, 95(1):277-291.
5. Berenson A. Cancer Drugs Offer Hope but at a Huge Expense 2005, New York Times, New York.
6. Berndt E.R., Cockburn I.M., Griliches Z. Pharmaceutical innovations and market dynamics: Tracing effects on price indexes for antidepressant drugs. Brookings Papers on Economic Activity 1996, 133-188.
7. Black W.C., Haggstrom D.A., Welch H.G. All-cause mortality in randomized trials of cancer screening. Journal of National Cancer Institute 2002, 94(3):167-173.
8. Blinder A.S. Wage discrimination: Reduced form and structural estimates. Journal of Human Resources 1973, 8(4):436-455.
9. Bloom H.J., Richardson W.W., Harries E.J. Natural history of untreated breast cancer (1805-1933). Comparison of untreated and treated cases according to histological grade of malignancy. British Medical Journal 1962, 2(5299):213-221.
10. Breen N., Wagener D.K., Brown M.L., et al. Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys. Journal of the National Cancer Institute 2001, 93(22):1704-1713.
11. Caves R.E., Whinston M.D., Hurwitz M.A. Patent expiration, entry, and competition in the u s pharmaceutical industry. Brookings Papers on Economic Activity 1991, 1-48.
12. Cutler D.M., Richardson E. Measuring the Health of the U.S. Population. Brookings Papers on Economic Activity 1997, 217-271.
13. Devlin N., Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 2004, 13(5):437-452.
14. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: New estimates of drug development costs. Journal of Health Economics 2003, 22(2):151-185.
15. Epstein S.S. Cancer-Gate: How to Win the Losing War on Cancer 2005, Baywood, Amityville, NY.
16. Espey D.K., Wu X.C., Swan J., et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer 2007, 110(10):2119-2152.
17. Faguet G.B. The War on Cancer: An Anatomy of a Failure, a Blueprint for the Future 2005, Springer, New York.
18. Gaynor M., Vogt W.B. Competition among Hospitals. Rand Journal of Economics 2003, 34(4):764-785.
19. Goldman D.P., Jena A.B., Lakdawalla D.N., et al. The value of specialty oncology drugs. Health Services Research 2010, 45(1):115-132.
20. Grabowski H., Vernon J.M. Brand loyalty, entry and price competition in pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics 1992, 35(2):331-350.
21. Hall R.E., Jones C.I. The value of life and the rise in health spending. Quarterly Journal of Economics 2007, 122(1):39-72.
22. Hillner B.E., Smith T.J. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?. Journal of Clinical Oncology 2007, 25(6):611-613.
23. Honore B.E., Lleras-Muney A. Bounds in competing risks models and the war on cancer. Econometrica 2006, 74(6):1675-1698.
24. Jaffe A.B. Trends and patterns in research and development expenditures in the United States. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(23):12658-12663.
25. Kolata G., Pollack A. Costly Cancer Drug Offers Hope, but Also a Dilemma 2008, New York Times, New York, NY.
26. Lee C.P., Chertow G.M., Zenios S. An empirical estimate of the value of life: Updating the renal dialysis cost-effectiveness standard. Value in Health 2009, 12(1):80-87.
27. Lichtenberg, F.R., 2004. The Expanding Pharmaceutical Arsenal in the War on Cancer. National Bureau of Economic Research, Inc, NBER Working Papers.
28. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289(1):76-79.
29. Moy C.S., Albert D.M., Diener-West M., et al. Cause-specific mortality coding. methods in the collaborative ocular melanoma study coms report no. 14. Controlled Clinical Trials 2001, 22(3):248-262.
30. Murphy K.M., Topel R.H. The value of health and longevity. Journal of Political Economy 2006, 114(5):871-904.
31. Nadler E., Eckert B., Neumann P.J. Do oncologists believe new cancer drugs offer good value?. The Oncologist 2006, 11(2):90-95.
32. Oaxaca R. Male-female wage differentials in urban labor markets. International Economic Review 1973, 14(3):693-709.
33. Philipson T.J., Jena A.B. Who benefits from new medical technologies? Estimates of consumer and producer surpluses for HIV/AIDS drugs. Forum for Health Economics & Policy 2006, 9(2).
34. Pulte D., Gondos A., Brenner H. Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century. Archives of Internal Medicine 2008, 168(5):469-476.
35. Raz D., Zell J., Ou I., et al. Natural history of stage I non-small cell lung cancer. Chest 2007, 132:193-199.
36. Shih Y.C., Halpern M.T. Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?. CA: A Cancer Journal for Clinicians 2008, 58(4):231-244.
37. Sun E., Jena A.B., Lakdawalla D., et al. The contributions of improved therapy and earlier detection to cancer survival gains, 1988-2000. Forum for Health Economics and Policy 2010, 13(2). Issue 1.
38. Welch H.G., Schwartz L.M., Woloshin S. Are increasing 5-year survival rates evidence of success against cancer?. JAMA 2000, 283(22):2975-2978.